Year: 2024

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective immediately. Mr. Weaver will lead the Company’s finance and accounting functions, including SEC reporting and investor relations. “We are pleased to welcome Greg to Altimmune’s executive team during such a pivotal time in our evolution. He has a wealth of experience that we believe will be invaluable as we enter a crucial period in the development of our lead program, pemvidutide and in our advancement as an organization,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We look forward to his contributions and are excited for the opportunity to leverage his expertise and broad industry...

Highlights significant potential for the Project; at a 0.40 g/t cut-off gold grade, the maiden mineral resource estimate totals:In Pit Measured & Indicated Mineral Resource: 81.348 million tonnes grading 0.61 g/t gold and 18.76 g/t silver (0.86 g/t gold equivalent*6), containing an estimated 1.593 million ounces of gold and 49.067 million ounces of silver (2.248 million ounces of gold equivalent*6); plus limited Inferred Mineral Resource.The estimate produces in- pit resources for the Northern Monserrat Sector and Southern Mineralized Corridor deposits, spaced just 5.0 km apart.Mineralization remains open in all directions and below the base of drilling at both the North and South sectors, showing clear scope for further drilling to increase the size of this initial mineral resource estimate.The resource estimate is based...

– FDA sets PDUFA Action Date of June 28, 2025 – Company Preparing for 2025 Commercial Launch – LOS ALTOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025. If approved, OLC has the potential to meaningfully improve the treatment burden for hyperphosphatemia patients with chronic kidney disease (CKD) on dialysis. “We are thrilled with the FDA acceptance of our first NDA, a significant milestone towards our efforts to bring this important treatment...

WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences: Stifel 2024 Healthcare Conference, New YorkMonday, November 18, 2024 at 3:35 PM ET Piper Sandler 36th Annual Healthcare Conference, New YorkWednesday, December 5, 2024 at 11:00 AM ET Live webcasts and replays, when available, can be found under “News / Events” in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcasts will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology...

VANCOUVER, British Columbia, Nov. 11, 2024 (GLOBE NEWSWIRE) — Sable Resources Ltd. (“Sable” or the “Company”) (TSXV:SAE | OTCQB:SBLRF) is pleased to announce that it has received additional positive surface results from its 100% owned Copper Queen Project in west-central British Columbia (“Copper Queen” or the “Property”). In addition, the Company has initiated a 520km VTEM time-domain survey covering the main target areas on the Property. HighlightsAn additional 40 previously unreported rock samples have been included in this new release along with results from the previously reported 97 rock samples that were collected within and around Breccias 1, 2, and 3 (see Figure 1). New results include maximum values of 1.07% Cu; 27.7 g/t Au; and 100 g/t Ag. Selected results for the present and previously reported...

WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) — Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of the management team will participate in two upcoming investor conferences. Jefferies London Healthcare Conference 1×1 meetings with Caroline Loew, Ph.D., CEO, Vicki Goodman, MD, Chief Medical Officer, Adam Cutler, Chief Financial Officer Date: Tuesday, November 19-Wednesday, November 20, 2024 Piper Sandler 36th Annual Healthcare Conference Fireside chat with Caroline Loew, Ph.D., CEO, Vicki Goodman, MD, Chief Medical Officer, and Adam Cutler, Chief Financial Officer Date: Wednesday, December 9, 2024 Time: 9:30 a.m. ET A...

Not for release to US wire services or distribution in the United States TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) — Xanadu Mines Ltd (ASX:XAM, TSX:XAM) (Xanadu or the Company) advises that on 8 November 2024, it issued 100,000,004 fully paid ordinary shares at a price of $0.055 per share, to a range of sophisticated investors under an Equity Placement led by Bell Potter Securities Limited and Ord Minnett Limited (New Shares). Xanadu Mines advises that: (a) the New Shares were issued without disclosure under Part 6D.2 of the Act; (b) this notice is being given under section 708A(5)(e) of the Act; (c) as at the date of this notice, Xanadu Mines has complied with: (1) the provisions of Chapter 2M of the Act as they apply to Xanadu Mines; and (2) sections 674 and 674A of the Act as they apply to Xanadu Mines; and (d) as at the date...

SAN DIEGO, CA, Nov. 11, 2024 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), a leading innovator of payment transaction solutions leveraging proprietary blockchain ledger and electronic payment technology for diverse international markets, has signed a non-binding Memorandum of Understanding (the “MOU”) with the investor (the “Investor”) setting forth the terms agreed to by the Company and the Investor for the full repayment and termination of an 8% Senior Convertible Note (the “Note) and the redemption of all shares of the Company’s Series B Convertible Preferred Stock (the “Preferred Stock”) held by the Investor. As of October 31, 2024, the outstanding Note principal was $19.0 million, and the liquidation value of the Preferred Stock was $53.5 million. Under the terms of the MOU,...